References
- Kupka D, Sibbing D. P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis. Expert Opin Drug Metab Toxicol. 2018;14:303–315.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213–260.
- Serebruany VL, Kim MH, Marciniak TA. Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration ESC. Eur Heart J Cardiovasc Pharmacother. 2018;4:6–9.
- Pehrsson S, Johansson KJ, Janefeldt A, et al. Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. J Thromb Haemost. 2017;15:1213–1222.
- Teng R, Carlson GF, Nylander S, et al. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects. J Thromb Haemost. 2016;14:2342–2352.
- Martin AC, Berndt C, Calmette L, et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol. 2016;33:361–367.
- Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med. 2015;372:196–197.
- Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–2273.
- Zhang Y, Huo M, Zhou J, et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306–314.
- Youmis IR. Ticagrelor clinical pharmacology and biopharmaceutics review. US Food and Drug Administration/Center for Drug Evaluation and Research. 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000-ClinPharmR.pdf
- Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–496.
- Hobl E-L, Derhaschnig U, Firbas C, et al. Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor. Eur J Clin Invest. 2013;43:1258–1261.
- Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299–2306.